These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 31652837)

  • 41. Design and Development of Autotaxin Inhibitors.
    Jia Y; Li Y; Xu XD; Tian Y; Shang H
    Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
    FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
    Schmid R; Wolf K; Robering JW; Strauß S; Strissel PL; Strick R; Rübner M; Fasching PA; Horch RE; Kremer AE; Boos AM; Weigand A
    BMC Cancer; 2018 Dec; 18(1):1273. PubMed ID: 30567518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis.
    Cao P; Aoki Y; Badri L; Walker NM; Manning CM; Lagstein A; Fearon ER; Lama VN
    J Clin Invest; 2017 Apr; 127(4):1517-1530. PubMed ID: 28240604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface.
    Peyruchaud O; Saier L; Leblanc R
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31906151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autotaxin and Lysophosphatidate Signaling: Prime Targets for Mitigating Therapy Resistance in Breast Cancer.
    Benesch MGK; Tang X; Brindley DN; Takabe K
    World J Oncol; 2024 Feb; 15(1):1-13. PubMed ID: 38274724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autotaxin inhibitors: a patent review (2012-2016).
    Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
    Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bronchopulmonary dysplasia demonstrates dysregulated autotaxin/lysophosphatidic acid signaling in a neonatal mouse model.
    Ha AW; Sudhadevi T; Jafri A; Mayer C; MacFarlane PM; Natarajan V; Harijith A
    Pediatr Res; 2024 Oct; ():. PubMed ID: 39415037
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation.
    Harper K; Arsenault D; Boulay-Jean S; Lauzier A; Lucien F; Dubois CM
    Cancer Res; 2010 Jun; 70(11):4634-43. PubMed ID: 20484039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
    Budd DC; Qian Y
    Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.
    Velasco M; O'Sullivan C; Sheridan GK
    Neuropharmacology; 2017 Feb; 113(Pt B):608-617. PubMed ID: 27059127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes.
    Sevastou I; Kaffe E; Mouratis MA; Aidinis V
    Biochim Biophys Acta; 2013 Jan; 1831(1):42-60. PubMed ID: 22867755
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
    Okudaira S; Yukiura H; Aoki J
    Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lysophosphatidic acid metabolism and signaling in heart disease.
    Jose A; Fernando JJ; Kienesberger PC
    Can J Physiol Pharmacol; 2024 Dec; 102(12):685-696. PubMed ID: 38968609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development.
    Valdés-Rives SA; González-Arenas A
    Mediators Inflamm; 2017; 2017():9173090. PubMed ID: 29430083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lysophosphatidic Acid Inhibits Insulin Signaling in Primary Rat Hepatocytes via the LPA3 Receptor Subtype and is Increased in Obesity.
    Fayyaz S; Japtok L; Schumacher F; Wigger D; Schulz TJ; Haubold K; Gulbins E; Völler H; Kleuser B
    Cell Physiol Biochem; 2017; 43(2):445-456. PubMed ID: 28922661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autotaxin--an LPA producing enzyme with diverse functions.
    Nakanaga K; Hama K; Aoki J
    J Biochem; 2010 Jul; 148(1):13-24. PubMed ID: 20495010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
    Orosa B; García S; Conde C
    Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Promising pharmacological directions in the world of lysophosphatidic Acid signaling.
    Stoddard NC; Chun J
    Biomol Ther (Seoul); 2015 Jan; 23(1):1-11. PubMed ID: 25593637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort study.
    Pleli T; Martin D; Kronenberger B; Brunner F; Köberle V; Grammatikos G; Farnik H; Martinez Y; Finkelmeier F; Labocha S; Ferreirós N; Zeuzem S; Piiper A; Waidmann O
    PLoS One; 2014; 9(7):e103532. PubMed ID: 25062038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.